An Overview of Transporter Information in Package Inserts of Recently Approved New Molecular Entities

被引：21
|
作者：
Agarwal, Sheetal [1 ]
Chinn, Leslie [1 ]
Zhang, Lei [1 ]
机构：
[1] US FDA, Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
来源：
PHARMACEUTICAL RESEARCH | 2013年 / 30卷 / 03期
关键词：
drug-drug interaction; labeling; package insert; regulatory; transporter;
D O I：
10.1007/s11095-012-0924-0
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：899 / 910
页数：12
相关论文
共 47 条
  • [31] New molecular entities/new biologics - FluMist - Intranasal influenza virus vaccine, live - Medimmune/Wyeth - First nasally delivered flu vaccine approved
    不详
    FORMULARY, 2003, 38 (07) : 395 - +
  • [32] Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015
    Chen, Alice
    Wright, Hilary
    Itana, Hawi
    Elahi, Merina
    Igun, Ayomide
    Soon, Guoxing
    Pariser, Anne R.
    Fadiran, Emmanuel O.
    JOURNAL OF WOMENS HEALTH, 2018, 27 (04) : 418 - 429
  • [33] Postmarketing Safety-Related Regulatory Actions for New Therapeutic Biologics Approved in the United States 2002-2014: Similarities and Differences With New Molecular Entities
    Bulatao, Ilynn
    Pinnow, Ellen
    Day, Brendan
    Cherkaoui, Sanae
    Kalaria, Manish
    Brajovic, Sonja
    Dal Pan, Gerald
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (06) : 1243 - 1253
  • [34] LEARNINGS FROM FDA CLINICAL PHARMACOLOGY (CP) REVIEWS OF ONCOLOGY (ONC) NEW MOLECULAR ENTITIES (NMES) APPROVED FROM 2011 TO 2015.
    Faucette, S.
    Trivedi, A.
    Gupta, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S93 - S93
  • [35] REVIEW OF RACIAL/ETHNIC DIFFERENCES IN PHARMACOKINETICS (PK), PHARMACOGENOMICS (PGX), SAFETY, AND EFFICACY OF NEW MOLECULAR ENTITIES APPROVED BETWEEN 2014 AND 2018.
    Ramamoorthy, A.
    Shah-Williams, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S105 - S105
  • [36] Participation of racial/ethnic groups in clinical trials and race-related labeling: A review of new molecular entities approved 1995-1999
    Evelyn, B
    Toigo, T
    Banks, D
    Pohl, D
    Gray, K
    Robins, B
    Ernat, J
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2001, 93 (12) : 18S - 24S
  • [37] ANALYSIS OF LABELING RECOMMENDATIONS IN SELECTED SPECIFIC POPULATIONS IN US FOOD AND DRUG ADMINISTRATION (FDA)-APPROVED NEW MOLECULAR ENTITIES BETWEEN 1998 AND 2017.
    Shugg, T.
    Faruque, F.
    Younis, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S106 - S106
  • [38] HOW DRUG-DRUG INTERACTIONS (DDIS) INFORM DRUG LABELING: A SURVEY OF APPROVED NEW MOLECULAR ENTITIES (NMES) FROM 1998 TO 2015.
    Shugg, T.
    Xu, J.
    Younis, I. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S47 - S47
  • [39] Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: Mechanisms leading to optimal efficacy and safety
    Swinney, David C.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (05) : 461 - 478
  • [40] EVALUATION OF PH-DEPENDENT DRUG-DRUG INTERACTIONS FOR WEAK BASE DRUGS: AN UPDATE FOR NEW MOLECULAR ENTITIES APPROVED IN 2013-2017.
    Li, J.
    Dong, Z.
    Wu, F.
    Zhang, L.
    Lee, S. -C.
    Zhang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S18 - S18
12345